Residue 116 determines the C-terminal anchor residue of HLA-B*3501 and -B*5101 binding peptides but does not explain the general affinity difference

Immunogenetics

Volumn 47, Issue 3, 1998, Pages 256-263

  Kubo, Hitomi ^a,e   Ikeda Moore, Yuki ^a   Kikuchi, Akiko ^a,f   Miwa, Kiyoshi ^b   Nokihara, Kiyoshi ^c   Schönbach, Christian ^a   Takiguchi, Masafumi ^a,d  

^a UNIVERSITY OF TOKYO   (Japan)

^b AJINOMOTO CO INC   (Japan)

^c Shimadzu Scientific Research Inc   (Japan)

^d KUMAMOTO UNIVERSITY   (Japan)

^e SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f JAPANESE RED CROSS MEDICAL CENTER   (Japan)

Author keywords

F pocket; HLA B35; HLA B51; HLA class I; Peptide

Indexed keywords

HLA B ANTIGEN; MUTANT PROTEIN; PEPTIDE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; PRIORITY JOURNAL; PROTEIN BINDING; STRUCTURE ACTIVITY RELATION;

BINDING SITES; CELL LINE; HLA-B ANTIGENS; HLA-B35 ANTIGEN; HUMANS; METHIONINE; MUTAGENESIS, SITE-DIRECTED; PEPTIDES; PHENYLALANINE; SERINE; TRANSFECTION; TYROSINE;

EID: 0031964544     PISSN: 00937711     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002510050355     Document Type: Article

References (29)

1. Brewerton, D. A., Caffrey, M., Hart, F. D., James, D. C. O., Nicholls, A., and Sturrock, R. D. Ankylosing spondylitis and HLA-A27. Lancet i: 904-907, 1973
2. D'Amato, M. T., Fiorillo, M. T., Carcassi, C., Mathieu, A., Zuccarelli, A., Bitti, P. P., Tosi, R., and Sorrentino, R. Relevance of residue 116 of HLA-B27 in determining susceptibility to ankylosing spondylitis. Eur J Immunol 25: 3199-3201, 1995
3. Falk, K., Rötzschke, O., Stevanovic, S., Jung, G., and Rammensee, H.-G. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351: 290-296, 1991
4. Falk, K., Rötzschke, O., Grahovac, B., Schendel, D., Stevanović, S., Jung, G., and Rammensee, H.-G. Peptide motifs of HLA-B35 and -B37 molecules. Immunogenetics 38: 161-162, 1993
5. Falk, K., Rötzschke, O., Takiguchi, M., Grahovac, B., Gnau, V., Stevanović, S., Jung, G., and Rammensee, H.-G. Peptide motifs of HLA-A1, -A11, -A31 and -A33 molecules. Immunogenetics 40: 238-241, 1994
6. Falk, K., Rötzschke, O., Takiguchi, M., Gnau, V., Stevanović, S., Jung, G., and Rammensee, H.-G. Peptide motifs of HLA-B51, -B52 and -B78 molecules, and implications for Behçet's disease. Int Immunol 7: 223-228, 1995
7. Hayashi, H., Ennis, P. D., Ariga, H., Salter, R. D., Parham, P., Kano, K., and Takiguchi, M. HLA-B51 and HLA-Bw52 differ by only two amino acids which are in the helical region of the a1 domain. J Immunol 142: 306-311, 1989
8. 2 domain. Immunogenetics 37: 95-101, 1993
9. Jardetzky, T. S., Lane, W. S., Robinson, R. A., Madden, D. R., and Wiley, D. C. Identification of self peptides bound to purified HLA-B27. Nature 353: 326-329, 1991
10. Kikuchi, A., Sakaguchi, T., Miwa, K., Takamiya, Y., Rammensee, H.-G., Kaneko, Y., and Takiguchi, M. Binding of nonamer peptides to three HLA-B51 molecules which differ by a single amino acid substitution in the A-pocket. Immunogenetics 43: 268-273, 1996
11. Kunkel, T. A. Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci USA 82: 488-492, 1985
12. Matsumoto, K., Yamamoto, J., Hiraiwa, M., Kano, K., and Takiguchi, M. Discrimination of HLA-B5 crossreactive group antigens by human allospecific CTL clones. Transplantation 49: 1164-1167, 1990
13. Mizuki, N., Inoko, H., Ando, H., Nakamura, S., Kashiwase, K., Akaza, T., Fujino, Y., Masuda, K., Takiguchi, M., and Ohno, S. Behçet's disease associated with one of the HLA-B51 subantigens, HLA-B*5101. Am J Ophthal 116: 406-409, 1993
14. Mizuki, N., Inoko, H., Ishihara, M., Ando, H., Nakamura, S., Nishino, M., and Ohno, S. A complete type patient with Behçet's disease associated with HLA-B*5102. Act Ophthalmol 72: 757-758, 1994
15. Nokihara, K., Yamamoto, R., Hazama, M., Wakizawa, O., and Nakamura, S. Design and applications of a novel simultaneous multiple solid-phase peptide synthesizer. In R. Epton (ed.): Innovation and Perspective in Solid-Phase Synthesis, pp.445, Intercept, Andover, 1992
16. Ohno, S., Aoki, K., Sugiura, S., Nakajima, E., Itakura, K., and Aizawa, M. HL-A5 and Behçet's disease. Lancet II-2: 1383-1384, 1973
17. Ohno, S., Asanuma, T., Sugiura, S., Wakisaka, A., and Aizawa, M. HLA-Bw51 and Behçet's disease. J Am Med Assoc 240: 529, 1978
18. Ooba, T., Hayashi, H., Karaki, S., Tanabe, M., Kano, K., and Takiguchi, M. The structure of HLA-B35 suggests that it is derived from HLA-Bw58 by two genetic mechanisms. Immunogenetics 30: 76-80, 1989
19. Parker, K. C., Bednarek, M. A., Hull, L. K., Utz, Y., Cunningham, B., Zweerink, H. J., Biddison, W. E., and Coligan, J. E. Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2. J Immunol 149: 3580-3587, 1992
20. Radka, S. F., Kostyu, D. D., and Amos, D. B. A monoclonal antibody directed against the HLA-Bw6 epitope. J Immunol 128: 2804-2806, 1982
21. Rötzschke, O., Falk, K., Stevanović, S., Gnau, V., Jung, G., and Rammensee, H.-G. Dominant aromatic/aliphatic C-terminal anchor in HLA-B*2702 and B*2705 peptide motifs. Immunogenetics 39: 74-77, 1994
22. Sakaguchi, T., Ibe, M., Miwa, K., Kaneko, Y., Yokota, S., Tanaka, K., and Takiguchi, M. Binding of 8-mer to 11-mer peptides carrying the anchor residues to slow assembling HLA class I molecules (HLA-B*5101). Immunogenetics 45: 226-228, 1947
23. Schönbach, C., Ibe, M., Shiga, H., Takamiya, Y., Miwa, K., Nokihara, K., and Takiguchi, M. Fine tuning of peptide binding to HLA-B*3501 molecules by nonanchor residues. J Immunol 154: 5951-5958, 1995
24. Schönbach, C., Miwa, K., Ibe, M., Shiga, H., Nokihara, K., and Takiguchi, M. Refined peptide-HLA-B*3501 binding motif reveals differences in 9-mer to 11-mer peptide binding. Immunogenetics 45: 121-129, 1996
25. 2 helix of MHC class I is revealed by the crystal structure of HLA-B*3501. Immunity 4: 203-213, 1996
26. Steinle, A., Falk, K., Rötzschke, O., Gnau, V., Stevanović, S., Jung, G., Schendel, D. J., and Rammensee, H.-G. Motif of HLA-B*3503 peptide ligands. Immunogenetics 43: 105-107, 1995
27. Tait, B. D., Naito, S., Boyle, A., Dupont, E., Andrien, M., Saitou, S., Miller, S., Scorza, R., Kalil, J., Grumet, C., Pitchappau, R. M., Bias, W., Cantwell, L., Bennett, G., Zachary, A., Garrido, F., and Maeda, H. Antigen Society no. 105: HLA-B5, -B51, -B52, -B18, -B35, -B53. In K. Tsuji, M. Aizawa and T. Sasazuki (eds.): HLA 1991, pp 297-305, Oxford Science Publications, Oxford, 1992
28. Takamiya, Y., Schönbach, C., Nokihara, K., Ferrone, S., Yamaguchi, M., Kano, K., Egawa, K., and Takiguchi, M. HLA-B*3501-peptide interactions: Role of anchor residues of peptides in their binding to HLA-B*3501 molecules. Int Immunol 6: 255-261, 1994
29. Tanabe, M., Sekimata, M., Ferrone, S., and Takiguchi, M. Structural and functional analysis of monomorphic determinants recognized by monoclonal antibodies reacting with the HLA class I a3 domain. J Immunol 148: 3202-3209, 1992